Loading
A phase 1/2 trial of Sonrotoclax, Zanubrutinib in mantle cell lymphoma, run by BeOne Medicines, now recruiting.
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. is a phase 1/2 interventional study registered as NCT06697184 by BeOne Medicines, with 258 participants planned, started 2025-01-23 and due to reach its primary completion in 2029-11-30. Interventions recorded: Sonrotoclax, Zanubrutinib. Conditions listed: Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL. No results are recorded here; the registry entry is the source.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene).
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors.